Hershey Claims GLP-1 Use Is Causing ‘Strong Demand’ for Its Gum and Mints

Hershey said GLP-1 adoption is boosting demand for gum and mints, with third-largest confection brand Ice Breakers retail sales up more than 8% in the quarter. CEO Kirk Tanner said the category is benefiting from functional snacking tailwinds and called Ice Breakers a potential billion-dollar brand. The article is mostly qualitative, but it points to a modestly positive demand trend for Hershey’s refreshment business.

Analysis

This is a subtle demand-signal, not just a novelty story. If GLP-1 adoption is materially changing basket composition, the first-order winner is not broad confectionery but “micro-indulgence” formats that solve freshness, breath, and mouthfeel needs in small-ticket, high-frequency use cases. That tends to favor brands with strong convenience-store, pharmacy, and checkout exposure more than big-box pantry staples, and it may also pull share from traditional candy into functional confection adjacencies over the next 6-18 months.

The second-order implication is margin mix. Gum and mints typically carry better unit economics than chocolate when input costs are stable and distribution is efficient, so a mix shift here can support gross margin even if headline category growth is modest. The market may be underestimating how persistent the GLP-1 effect is: once consumers associate these products with a functional need, repeat purchase can outlast the initial medication cycle, creating a semi-structural demand layer rather than a one-time spike.

The main risk is that this thesis is overcrowded in narrative but not yet in data. If breath/refreshment demand is driven by a relatively small subset of users, the revenue uplift may be too narrow to move the consolidated P&L, and any deceleration in GLP-1 prescriptions or switching to higher-dose regimens that reduce snacking frequency could flatten the effect over the next 2-3 quarters. Also, if competitors lean into similar formulations or private label aggressively, HSY may see volume gains without much pricing power.

Contrarian view: the market may be overfitting a health-side-effect story to a category that was already benefiting from convenience and impulse occasions. The cleaner thesis is not “Ozempic breath” per se, but that GLP-1s are accelerating a broader shift toward low-calorie, portion-controlled, function-labeled snacking. If that is right, the opportunity extends beyond HSY into adjacent snack and oral-care names, while the risk is that consensus overpays for the most obvious beneficiary before the data proves the elasticity.

Key Decisions for Investors

• Long HSY on 3-6 month horizon into print-follow-through, but size modestly: the GLP-1 uplift is real enough to support estimate revisions, yet likely too small to re-rate the whole multiple by itself.
• Pair trade: long HSY / short a higher-beta packaged snack peer with more exposed legacy indulgence mix for 1-2 quarters, targeting relative outperformance if functional-snacking share keeps migrating.
• Buy HSY call spread 3-6 months out rather than outright stock if you want convexity on a broader functional-snacking re-rate; the upside is estimate expansion, not a step-change in fundamental growth.
• Watch for confirmation in convenience-store scanner data and pharmacy-channel sell-through over the next 60-90 days; if repeat purchase does not broaden beyond early adopters, fade the move.
• Contrarian hedge: long an oral-care beneficiary basket versus HSY if you believe the true spending impulse from GLP-1 users shifts more toward breath-freshening and hygiene than confection consumption.